Clinical trial · Interventional
Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Evaluation of Diagnostic Value of 3-T MRI in Suspected Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the usefulness of 3-T magnetic resonance imaging (MRI) in the evaluation of suspected prostate cancer. Men with suspected prostate cancer based on serum prostate-specific antigen antigen (PSA) value are included. Men are randomized to pre-biopsy MRI or no MRI groups in ratio 1:1. Standard transrectal ultrasound guided biopsies will be taken in addition to extra biopsies from lesions suspicious based on MRI evaluation. Hypothesis is that more prostate cancers will be found after MRI evaluation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| magnetic resonance imaging, Siemens | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MRI done
- description
- Subjects with MRI prior prostate biopsies
- interventionNames
- Device: magnetic resonance imaging, Siemens
- type
- NO_INTERVENTION
- label
- no MRI
- description
- No MRI before prostate biopsies
Primary outcomes (1)
- measure
- Number of Prostate Cancer Diagnoses in MRI and no MRI Groups
- timeFrame
- at the end of the study (up to 1 year)
- description
- The number of patients with confirmed prostate cancer among men with MRI performed before biopsies are compared to the number of patients with prostate cancer confirmed in prostate biopsies without MRI. The number patients with prostate cancer are counted as total from cancers detected in random biopsies and in biopsies targeted based on suspicious MRI findings in MRI group, and from random biopsies in no MRI group.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent * Suspected prostate cancer based on PSA value (total PSA 2,5-10 ng/ml and PSA free to total ratio \<=0.15, or total PSA 10-20 ng/ml) * PSA and serum creatinine measurement less than 60 days before transrectal ultrasound-guided prostate biopsies * No evidence of PSA increase by non-cancerous factors (catheterization, bladder stones, urinary tract infection including bacterial prostatitis) Exclusion Criteria: * Previous prostate biopsies * Previous prostate surgery * Contraindication for MRI (such as pacemaker or inner ear implant) * Claustrophobia * Estimated glomerular filtration rate (eGFR) \<40 ml/min * Suspected clinical T3-T4 prostate cancer based on digital rectal examination * Contraindication for transrectal ultrasound-guided prostate biopsies * body mass index \>30
References
Publications (1)
- DERIVEDTonttila PP, Lantto J, Paakko E, Piippo U, Kauppila S, Lammentausta E, Ohtonen P, Vaarala MH. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur Urol. 2016 Mar;69(3):419-25. doi: 10.1016/j.eururo.2015.05.024. Epub 2015 May 29. PMID 26033153